AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

David A. Sallman, Adam Asch, Suman Kambhampati, Monzr Al Malki, Joshua F. Zeidner, William B. Donnellan, Daniel Lee, Paresh Vyas, Deepa Jeyakumar, Gabriel N. Mannis, Tiffany Tanaka, Wanxing Chai‐Ho, Richard A. Larson, Andrew R. Whiteley, Guido Marcucci, Rami S. Komrokji, Guillermo Garcia‐Manero, Joanna Van Elk, Ming‐Yen Lin, Roy L. Maute, Jens-Peter Volkmer, Chris H. Takimoto, Mark P. Chao, Naval Daver